This suggests that when anti-PD-1, anti-CTLA-4 or anti-PD-1/anti-CTLA-4 in combination is used alone, tumor cells can develop immune resistance through compensatory upregulation of the immunosuppressive molecule LAG-3 and reduce the therapeutic effect. This evidence concerns the gene LAG3 and neoplasm.